What is STIM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.16B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for STIM?

P/E (TTM) is n/a and 52-week range is $0.80 to $3.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s STIM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for STIM?

The company profile lists revenue (TTM) near $148M, net income (TTM) near $-2.90B, EPS (TTM) near $-0.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Neuronetics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Malvern, Pennsylvania, US, 69.6M shares outstanding, ISIN US64131A1051 when available from company profile and filing metadata.

Neuronetics Inc

$STIM

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$2.13

-0.47%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 658 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.

Employees

658

Website

neurostar.com/neuronetics/

IPO

2018-06-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)